To report the development of optic neuropathy after botulinum A toxin injection for restrictive myopathy from thyroid-related orbitopathy (TRO).
T hyroid-related orbitopathy (TRO) is a complex autoimmune disorder with multiple ophthalmic manifestations. Extraocular muscle involvement is one of the cardinal features of the disease and occurs in approximately 43% of all TRO patients. 1 The inferior and medial rectus muscles are the most commonly affected groups, and clinically this is evident by restrictive myopathy and elevated intraocular pressure with upgaze. 2, 3 The restrictive myopathy of TRO is initially observed without surgery and may spontaneously resolve in 1 to 2 years. 4 Surgical correction is typically delayed for 6 months to 12 months until stability is established and primarily consists of recession of the restricted inferior and/or medial rectus muscles. [5] [6] [7] [8] The degree of strabismus can be quite severe, and in the presence of disfiguring and congestive exophthalmos strabismus surgery is delayed until orbital decompression surgery is performed. 9, 10 In this interim period, botulinum A toxin injections can play an important role in alleviating symptoms of diplopia.
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Botulinum A toxin is a potent neurotoxin from Clostridium botulinum that selectively inhibits release of acetylcholine-containing vesicles in the neuromuscular junction. 12 The use of botulinum A toxin as an adjunct in the management of TRO complications has been well described. 11 Numerous reports have documented the improvement in the restrictive myopathy of TRO with botulinum A toxin injection to restricted extraocular muscles. [13] [14] [15] [16] [17] Symptomatic upper eyelid retraction and exposure keratopathy have also been reported to improve with botulinum A toxin injection to the upper eyelid. 18 -20 Simonsz and Vingerling reported a patient with compressive optic neuropathy who appeared to improve after botulinum A toxin injection. 21 We previously reported that botulinum A toxin injection to restricted extraocular muscles causes a decrease in intraocular pressure presumably owing to sarcomere relaxation. 2 Common side effects of botulinum A toxin injection include ptosis, strabismus, diplopia, pain, and tearing. [22] [23] [24] Necrotizing fasciitis has also been reported as a rare complication of botulinum A toxin injection in an elderly diabetic patient with blepharospasm. 25 To date, there have been no reported cases of botulinum A toxin associated with optic neuropathy. In this study, we report on 3 patients who developed optic neuropathy after injection of botulinum A toxin for restrictive strabismus in TRO.
METHODS
All patients were examined at the Thyroid Eye Center at the University of California at San Diego, a tertiary referral practice. This study was approved by the University of California, San Diego Human Research Protections Program. The records of 3 patients with restrictive myopathy secondary to TRO who underwent botulinum A toxin injection and subsequently developed evidence of optic neuropathy were reviewed and analyzed retrospectively. The following data were collected for each patient: medical history, thyroid status, best corrected Snellen visual acuity, color vision testing, pupillary responses, intraocular pressure measurement in primary gaze and upgaze, prism cover testing, ocular motility, anterior and posterior segment examination, eyelid position, exophthalmometry, visual field testing, and orbital imaging. The Naugle exophthalmometer (Oculus, Inc., Lynnwood, WA, U.S.A.) was used to measure globe position using the superior and inferior orbital rims as landmarks. Color vision testing was performed with the Hardy-Rand-Rittler (HRR) or Ishihara pseudoisochromic color plates (Richmond Products, Albuquerque, NM, U.S.A.). Threshold visual field testing using the SITA standard 24-2 protocol was performed with the Humphrey Systems Field Analyzer II (Carl Zeiss Meditec, Dublin, CA, U.S.A.).
We defined optic neuropathy as the presence of an afferent pupillary defect, decreased color vision, appearance of a new visual field defect, or decreased visual acuity, or by the appearance of the optic nerve. Orbital decompression surgery was performed as previously described. 9 Postoperatively, patients received oral methylprednisolone given as a 6-day tapered course and oral antibiotics.
Chemodenervation was performed with 5 U to 15 U botulinum A toxin (Botox, Allergan, Irvine, CA, U.S.A.) to the specified extraocular muscle. Injections were performed under topical anesthesia using electromyographic guidance to confirm placement of the toxin in the extraocular muscle. All injections were well tolerated. To prevent migration of the botulinum A toxin in the superior rectus complex, patients were instructed to sleep sitting up for 2 days following injection. Patients were examined 3 weeks after injection, corresponding to the peak onset of botulinum A toxin action. 13, 14 CT scanning was performed using a Lightspeed scanner with contiguous 3-mm axial and direct coronal scans through the orbit (General Electric Healthcare, Chalfont St. Giles, UK). All CT examinations were performed after injection of botulinum A toxin and the development of optic neuropathy. The following CT measurements were obtained: optic nerve crowding, extraocular muscle index, superior ophthalmic vein dilation, anterior displacement of lacrimal gland, and intracranial orbital fat prolapse.
The degree of optic nerve crowding was assessed using a scale as previously described. 26 In this scale, Grade 0 denotes no effacement of the perineural orbital fat planes by the extraocular muscles, Grade 1 (mild) denotes 1% to 25% effacement, Grade 2 (moderate) denotes 25% to 50% effacement, and grade 3 (severe) denotes Ͼ50% effacement.
The extraocular muscle index is a percentage of volume represented by the extraocular muscles over the horizontal and vertical dimension of the orbit and was calculated as previously described.
27,28 Figure 1 demonstrates a sample muscle index calculation. Using coronal images, the median distance between the posterior globe and orbital apex is identified. The transverse dimensions of the medial and lateral rectus muscles are then summed and divided by the horizontal width through the optic nerve. The analogous calculation is performed in the vertical dimension. The final muscle index is the greater of the 2 ratios.
Anterior displacement of the lacrimal gland is present if greater than 50% of the gland is displaced anterior to the frontozygomatic process. 26 Intracranial orbital fat prolapse is present if fat is seen posterior to the inner border of the superior ophthalmic fissure on axial CT imaging. 
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botulinum A toxin were delivered in the right inferior rectus muscle. The patient tolerated the procedure well and was discharged to home. Three weeks after botulinum A toxin injection, the patient presented with a complaint of decreased vision in the right eye. Snellen acuity measurement showed a decrease in vision to 20/60 OD with the onset of a new RAPD. Exophthalmometry showed no change after injection of botulinum A toxin. Automated visual field testing OD demonstrated inferior field defects while visual field testing was normal in the fellow eye (Fig. 2) . Orbital CT demonstrated bilateral intracranial fat prolapse, grade 3 optic nerve effacement, a muscle index of 67%, lacrimal gland prolapse, and a dilated superior ophthalmic vein (Fig. 3) .
The patient was diagnosed with compressive optic neuropathy OD and immediately started on 40 mg oral prednisone. Based on the degree of optic neuropathy, a 3-wall orbital decompression with fat decompression was performed. The surgery was unremarkable, and postoperatively the patient noted marked improvement in vision. Visual acuity of the right eye returned to baseline at 20/30 with resolution of the relative afferent pupillary defect. Exophthalmometry of the right eye measured 16 mm after orbital decompression. The patient remains stable at 1 year follow up. 
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tion in proptosis was noted OS. At 3 years' follow-up, there is no evidence of optic neuropathy. Orbital CT demonstrated grade 3 effacement of the right optic nerve, a muscle index of 66%, and intracranial fat prolapse, whereas the left orbit showed a muscle index of 57%.
Oral prednisone at a dosage of 60 mg per day was initiated. Within 2 weeks of medical therapy, the dyschromatopsia resolved, the pupillary examination returned to normal, and the disc edema resolved. Radiotherapy consisting of 2,000 cGy was delivered to the right orbit with gradual tapering of the oral prednisone. Three-wall orbital decompression was performed on the right orbit several months later, resulting in a reduction of 9 mm of proptosis. At 5 years' follow-up, there is no evidence of optic neuropathy.
DISCUSSION
We report the first case series to describe optic neuropathy associated with botulinum A toxin treatment for the restrictive myopathy of TRO. The reasons for this association are unclear but we propose 3 possibilities. The first possible mechanism is by simple mass effect. Botulinum A toxin is supplied as a lyophilized powder and must be reconstituted with an aqueous diluent. Direct injection of the toxin in extraocular muscles increases the orbital volume. In the setting of an already tight orbital apex, even minute volumes such as 0.2 mL botulinum A toxin used in our patients may be sufficient to compromise optic nerve function. Alternatively, a larger mass effect may have been exerted by a hematoma caused by injection-induced intramuscular vessel trauma.
A second possible mechanism is that botulinum A toxin may induce an unfavorable configuration of the extraocular muscles, predisposing to apical compression. Experimental injection of botulinum A toxin in monkey extraocular muscles induced hypertrophy owing to mitochondrial dispersion. 29 Furuse et al. noted similar changes in rabbit extraocular muscle morphology after botulinum A toxin injection. 30 After blockage of neuromuscular transmission by botulinum A toxin, enzymatic oxidation of muscle fibers is decreased, causing associated capillary network shrinkage, local ischemia, and subsequent swelling of tissues. The resultant extraocular muscle hypertrophy after botulinum A toxin may therefore further compress the orbital apex. Alternatively, botulinum A toxin may be changing extraocular muscle configuration by stimulating further orbital inflammation. Botulinum A toxin is a bacterial protein, and while typically well tolerated, introduction of this foreign material in the inflamed thyroid orbit may induce further extraocular muscle hypertrophy from increased inflammation. Of note, all patients receiving botulinum A toxin in this study had never received prior treatment for 
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cosmetic or functional applications. In addition, none of the patients had prior evidence of optic neuropathy and had stable visual acuity for several months prior to receiving the botulinum A toxin injections. A final and remote possibility is that botulinum A toxin may be causing a direct or indirect toxic effect on optic nerve function. Berliocchi and colleagues recently noted that botulinum A toxin incubation to cultured mouse cerebellar granule cells disrupted synapses and induced neuronal apoptosis. 31 After botulinum A toxin is injected to target extraocular muscles, minute extravasation of the toxin from the muscle belly may result in diffusion of the toxin to the optic nerve and lead to optic nerve cell death. Alternatively, botulinum A toxin may have been inadvertently injected in the optic nerve, although this is unlikely because the injection is done under electromyographic guidance. In each of our patients, corticosteroid treatment was initiated prior to orbital surgery. While decompression alone would not be expected to reverse this putative neurotoxic mechanism, the pretreatment with corticosteroids may account for the clinical improvement.
In two of our study patients, inferior field defects were noted after botulinum A toxin injection. None of the patients received toxin injection to the superior rectus muscle, and on CT scan there was relative sparing of superior rectus muscle enlargement compared with the inferior and medial rectus muscles. The mechanism for this field change is unclear and a review of the literature reveals no studies correlating optic nerve compression with development of specific scotomas. It is possible that the superior portion of the optic nerve is more susceptible to compressive damage, and with apical crowding and upward displacement of the optic nerve, inferior field defects result. Furthermore, this field change could be explained by the hypothesis that the superior rectus muscle is less compliant than the other affected muscles. Extraocular muscle enlargement in TRO occurs by accumulation of glycosaminoglycans, which results in increased hydration and enlargement of the muscles. These affected muscles may be more pliable than the unaffected muscles and cause upward displacement of the optic nerve against the more rigid superior rectus.
Regardless of the mechanism, we noted several important features on orbital imaging in our optic neuropathy patients (Table) . Several studies have correlated the size of extraocular muscles on CT images with optic neuropathy. [26] [27] [28] [32] [33] [34] [35] [36] [37] Other quantitative CT measurementssuch as orbital apex crowding, proptosis, lacrimal gland prolapse, superior ophthalmic vein dilation, and intraorbital fat herniation through the superior ophthalmic fissurehave been reported as sensitive indicators for optic neuropathy. 26, 28, 32, 38, 39 In our series, we noted a muscle index greater than 50%, grade 3 optic nerve crowding, and intracranial fat prolapse in the superior ophthalmic fissure in all three patients. Prolapse of the lacrimal gland and superior ophthalmic vein dilation were variably seen in our study group.
We currently obtain orbital imaging on all patients prior to botulinum A toxin injection. If CT scan demonstrates muscle indexes greater than 50%, grade 3 optic nerve crowding, or signs of intracranial fat prolapse, botulinum A toxin injection is deferred. In these highrisk patients, orbital decompression is first performed if symptomatic exophthalmos is present, followed by strabismus surgery. All patients undergoing botulinum A toxin injection are followed weekly for development of any signs of optic neuropathy. If any patient does develop optic neuropathy, corticosteroid treatment will be initiated until orbital decompression can be considered.
Once we noted optic neuropathy after toxin injection, we initiated steroids in all study patients. Cases 1 and 2 did not show clinical improvement with steroids, whereas Case 3 did show resolution of the RAPD after steroid administration. Although we considered delaying subsequent treatment for several months to allow the botulinum A toxin to wane, we did not want to risk prolonging the optic neuropathy. Also, each of the patients had significant exophthalmos and congestive orbitopathy, thus orbital decompression was performed. In all cases, return of vision was noted as well as improved ocular surface symptoms and cosmesis.
The study is limited by its retrospective nature, the small number of cases, and lack of suitable controls. Preoperative CT scan was not performed on any of the patients, and hence we were unable to compare radiographic parameters before and after injection. Furthermore, it is possible that these patients may have been treated during the active phase of their disease manifesting with strabismus, and that the optic neuropathy was part of the natural history of their disease. This possibility is lessened by the fact that the optic neuropathy was only observed in the injected orbit with the higher degree of optic nerve crowding compared with 
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the other side. Future studies will be directed toward correlating preoperative orbital imaging and comparing quantitative measurements of muscle dimensions before and after injection of botulinum A toxin. Finally, the development of an animal model for thyroid-related orbitopathy will greatly facilitate our understanding of this disease process and help to tailor safer treatments for our patients.
